comparemela.com

Latest Breaking News On - Synthetic virus - Page 1 : comparemela.com

Dr Judy Mikovits: Never bypass innate immune response, never get the COVID shot – Brighteon TV

Well-known molecular biologist Dr. Judy Mikovits told the public they should never bypass innate immune response and never get another Wuhan coronavirus (COVID-19) shot in an interview with [.]

Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass

Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass. pipeline of intratumorally and intravenously administered viral immunotherapies – Initial phase of site buildout anticipated to be completed in fourth quarter 2021 Company anticipates site will be fully operational in early 2023 and expects to employ up to 100 Oncorus team members CAMBRIDGE, Mass., Jan. 04, 2021 Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, announced today that it has signed a 15-year lease to build a state-of-the-art, 88,000 square foot Good Manufacturing Practice (GMP) viral immunotherapy clinical manufacturing facility in Andover, Mass. Oncorus is advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple cancer indications with significant unmet needs based on its oncolytic Herpes S

Oncorus Appoints Scott Canute to its Board of Directors

Oncorus Appoints Scott Canute to its Board of Directors Oncorus Appoints Scott Canute to its Board of Directors CAMBRIDGE, Mass., Dec. 14, 2020 Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Scott Canute, M.B.A. to its Board of Directors. Mr. Canute has nearly 40 years of broad experience in the biopharmaceutical industry, including leading global manufacturing and operations strategy and execution for Genzyme Corporation and Eli Lilly and Company. “As we execute on our growth plans, including the buildout of our in-house manufacturing capabilities, we are delighted to welcome Scott Canute to our Board of Directors,” said Theodore (Ted) Ashburn, M.D., Ph.D., President and CEO of Oncorus. “We look forward to leveraging Scott’s breadth of experience and insights from leading operations and manufacturing for world-class bi

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.